NEWS
Bioprinting Laboratories Inc. awarded $285,000 NIH/NIEHS SBIR Phase I grant for developing genetically engineered human liver organoids to assess hepatotoxicity among poor and ultrafast metabolizers.
Bioprinting Laboratories Inc. has been relocated to Dallas, Texas.
Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research.
Dr. Lee received “Third Place Award” in Business Plan Competition at TERMIS-AM 2023 Conference.
Bioprinting Laboratories Inc. received $1 million angel investment for commercialization of pillar/perfusion plates for human organoid culture and analysis.
Dr. Lee is selected as a Cohort of BioNTX Tech Transfer Office Showcase and Pitch Competition at 2022 iC3 Life Science Summit.
Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research.
Bioprinting Laboratories Inc. awarded $50,000 grant from Colgate-Palmolive for antimicrobial research.
Dr. Lee and his research collaborators at Cincinnati Children’s Hospital Medical Center and University of Illinois at Chicago awarded $5.35 million NIH/NIDDK UH3 grant for modeling type II diabetes on pillar/perfusion plate platforms.
Bioprinting Laboratories Inc. awarded $838,000 NIH/NCATS SBIR Phase II grant for commercializing pillar/perfusion plate platforms for robust organoid culture and analysis.
Dr. Lee awarded $100,000 TeCK Fund grant for commercialization of microarray 3D bioprinting technology.
Dr. Lee established Bioprinting Laboratories Inc. to commercialize “microarray 3D bioprinting” technology.
Dr. Lee's team is selected as 2017 Cohort of I-Corps@Ohio program. In this program, Dr. Lee and his team members will develop business strategy and market analysis for commercializing a 384-pillar plate with sidewalls for miniaturized human tissue regeneration.